Share This Page
Drug Price Trends for FIORICET
✉ Email this page to a colleague
Average Pharmacy Cost for FIORICET
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FIORICET 50-300-40 MG CAPSULE | 52544-0080-01 | 8.82367 | EACH | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for FIORICET
What is FIORICET?
Fioricet (acetaminophen, butalbital, and caffeine) is a combination medication indicated primarily for the treatment of tension headaches. It has been marketed since the 1980s and is available via prescription in the United States. Fioricet's formulation includes:
| Component | Standard Dose |
|---|---|
| Acetaminophen | 300 mg |
| Butalbital | 50 mg |
| Caffeine | 40 mg |
Market Size and Demand Drivers
US Market Overview
- Prescription volume: Approximately 2 million prescriptions annually (IQVIA, 2022).
- Indication: Tension headaches, a common disorder affecting an estimated 80 million Americans.
- Market growth factors:
- Rising prevalence of tension headaches.
- Increased awareness of migraine and headache treatments.
- Limitations of current therapies leading to steady demand for combination drugs like Fioricet.
Competitive Landscape
- Major competitors:
- Analgesics like acetaminophen alone.
- Other combination drugs such as Norco (acetaminophen/hydrocodone) and Excedrin (acetaminophen, aspirin, caffeine).
- Emerging options: triptans, gepants, CGRP inhibitors.
- Market challenges:
- Regulatory restrictions on butalbital due to abuse potential.
- Concerns over acetaminophen-related hepatotoxicity.
- Shift toward non-opioid, non-barbiturate treatments.
Regulatory and Prescriber Trends
- Regulation: FDA has issued warnings about butalbital dependency and abuse.
- Prescriber behavior: Increasing caution with barbiturates limits prescriptions.
- Reimbursement: Moderate, with insurance coverage common but subject to formulary restrictions.
Price Points and Cost Analysis
Current Price Range
| Parameter | Estimated Price |
|---|---|
| Retail (cash price) for 30 pills | $25 - $50 (approximately $0.83 - $1.67 per pill) |
| Medicaid reimbursement rate | Approximately $15 - $30 per prescription |
| Commercial insurance | Variable, with copays ranging from $10 - $30 |
Price Comparison with Competitors
| Drug | Typical Cost (30 pills) | Notes |
|---|---|---|
| Fioricet | $25 - $50 | Prescription-specific, varies by pharmacy |
| Excedrin (OTC) | $4 - $10 | Over-the-counter, but not prescription |
| Triptans (e.g., sumatriptan) | $60 - $120 | Higher per dose, often more effective for migraine |
Factors Influencing Price Trends
- Regulatory pressure: Could lead to increased costs due to reformulation or adverse event mitigation.
- Manufacturing costs: Slight increases due to supply chain constraints or regulatory compliance.
- Market demand: Steady due to high prevalence but limited by prescriber restraint.
Price Projection Outlook
Short-Term (Next 1–2 Years)
- Price stability: Expected to remain within the current range due to consistent demand and regulatory environment.
- Impact of regulatory change: Potential for marginal increases if reformulation or added safety measures are required.
Medium-Term (3–5 Years)
- Price decline: Possible if new, safer, and more effective formulations replace current FIORICET.
- Price increase: Marginal if supply chain issues or increased regulatory barriers raise costs.
Long-Term (5+ Years)
- Market decline: Likely if alternative therapies gain widespread adoption or if prescriber preference shifts away from combination barbiturate medications.
- Market stabilization: Possibly if FIORICET remains a preferred option for specific patient subsets.
Key Market Dynamics
- Increased regulatory scrutiny on barbiturates could reduce prescriber frequency, leading to lower sales volumes.
- New therapies for tension headaches, such as CGRP inhibitors, may encroach on FIORICET’s market share.
- Price adjustments will depend on the evolution of formulary access, insurance policies, and generic competition.
Conclusion
Fioricet's market faces pressure from regulatory concerns, emerging therapies, and changing prescriber habits. Its current pricing remains stable but limited by these factors. Future price trajectories depend heavily on regulatory developments and market acceptance relative to alternatives.
Key Takeaways
- Fioricet holds a steady market mainly driven by tension headache prevalence.
- Regulatory concerns about butalbital could limit future prescribing and impact pricing.
- Prices for Fioricet are in the $25–$50 range for a 30-pill supply, with modest fluctuations expected.
- Alternative therapies and evolving treatment guidelines could suppress demand over the next five years.
- Price projections suggest relative stability in the short term but potential decline long-term if substitution trends accelerate.
FAQs
1. Will the price of Fioricet increase due to regulatory changes?
Potentially, if new regulations mandate reformulation or add safety measures, costs could rise, affecting retail prices. However, current data do not suggest immediate regulatory-driven price jumps.
2. Are generic versions influencing Fioricet’s price?
Yes. Generics are available, and increased competition typically drives prices down. The presence of generics keeps retail costs closer to $25–$30 for a 30-pill supply.
3. How does Fioricet’s price compare to emerging migraine therapies?
Emerging triptans and CGRP inhibitors are more expensive per dose but often more effective. prices for triptans range from $60 to $120 per dose, making Fioricet a more cost-effective option for certain patients.
4. Is there a risk of supply shortages affecting prices?
Supply chain disruptions could affect availability, leading to price volatility. However, currently, supply is stable with multiple manufacturing sources.
5. Will insurance coverage influence the future price of Fioricet?
Insurance and formulary decisions impact out-of-pocket costs more than the manufacturer’s list price. Better coverage reduces patient costs, but formulary restrictions could limit access, indirectly influencing demand and pricing.
[1] IQVIA. (2022). Market Data for Prescription Drugs in the United States.
More… ↓
